Arecor Therapeutics PLC Exercise of options and PDMR dealing (6008F)
November 08 2022 - 2:00AM
UK Regulatory
TIDMAREC
RNS Number : 6008F
Arecor Therapeutics PLC
08 November 2022
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Exercise of rollover options, PDMR dealing and Total Voting
Rights
Cambridge, UK, 8 November 2022: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives , announces that it has issued and allotted
131,433 new Ordinary Shares of 1 pence each in the share capital of
the Company following an exercise of options on 7 November 2022 at
an exercise price of 1 pence per Ordinary Share. The options
exercised were part of the rollover of share options previously
granted under the historic Arecor Limited EMI Share Option Plan
2018 ("Option Rollover"). Details of the Option Rollover are set
out in the Company's Admission Document.
Included in the exercise of options were options over 109,958
ordinary shares held by Directors/PDMRs of the Company as detailed
in the table below:
Director/ PDMR Position Existing Number of Resultant Rollover
interest in Options over interest in options
Ordinary Shares Ordinary Ordinary Shares remaining
Shares after exercise
exercised
David Gerring VP, Development 151,292 3,334 154,626 0
------------------- ------------------ ----------------- ------------------ -----------------
Chief Executive
Sarah Howell Officer 847,072 20,666 867,738 0
------------------- ------------------ ----------------- ------------------ -----------------
Chief Scientific
Jan Jezek Officer 404,474 3,334 407,808 0
------------------- ------------------ ----------------- ------------------ -----------------
VP, Clinical &
Regulatory
Fiona Lawrence Affairs 70,334 1,666 72,000 0
------------------- ------------------ ----------------- ------------------ -----------------
Chief Financial
Susan Lowther Officer 139,849 62,000 201,849 0
------------------- ------------------ ----------------- ------------------ -----------------
James VP, Business
MacDonald-Clink Development 25,000 18,958 43,958 16,042
------------------- ------------------ ----------------- ------------------ -----------------
Admission
Following the above transactions, application has been made for
the 131,433 new Ordinary Shares to be admitted to trading on AIM
("Admission") and dealings are expected to commence on, or around,
11 November 2022. The new Ordinary Shares will rank pari passu with
the Company's existing Ordinary Shares.
The total number of Ordinary Shares in issue following Admission
will be 30,618,183 accordingly, the figure of 30,618,183 may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure and Transparency Rules.
For further information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited Tel: +44 (0) 20 7886 2500
(NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
Details of the person discharging managerial responsibilities/person
closely associated
a) Name: a) David Gerring
b) Sarah Howell
c) Jan Jezek
d) Fiona Lawrence
e) Susan Lowther
f) James MacDonald-Clink
--------------------------------- -----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status: a) VP, Development
b) Chief Executive Officer
c) Chief Scientific Officer
d) VP, Clinical & Regulatory
Affairs
e) Chief Financial Officer
f) VP, Business Development
--------------------------------- -----------------------------------------
b) Initial notification/Amendment: Initial notification
--------------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name: Arecor Therapeutics plc
--------------------------------- -----------------------------------------
b) LEI: 98450093D12I3A8DDD58
--------------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 1 pence
instrument, type of instrument: each
Identification code: GB00BMWLM973
--------------------------------- -----------------------------------------
b) Nature of the transaction: Exercise of options over ordinary
shares
--------------------------------- -----------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
a) GBP0.01 a) 3,334
----------
b) GBP0.01 b) 20,666
----------
c) GBP0.01 c) 3,334
----------
d) GBP0.01 d) 1,666
----------
e) GBP0.01 e) 62,000
----------
f) GBP0.01 f) 18,958
----------
--------------------------------- -----------------------------------------
d) Aggregated information:
* Aggregated volume: 109,958
GBP0.01
* Price:
--------------------------------- -----------------------------------------
e) Date of the transaction: 07 November 2022
--------------------------------- -----------------------------------------
f) Place of the transaction: London Stock Exchange, AIM
Market (XLON)
--------------------------------- -----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDDBDBRGGDGDR
(END) Dow Jones Newswires
November 08, 2022 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024
